Aimei Health Technology Co., Ltd Ordinary Share (AFJK) - Total Liabilities
Based on the latest financial reports, Aimei Health Technology Co., Ltd Ordinary Share (AFJK) has total liabilities worth $4.53 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aimei Health Technology Co., Ltd Ordinar liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Aimei Health Technology Co., Ltd Ordinary Share - Total Liabilities Trend (2023–2025)
This chart illustrates how Aimei Health Technology Co., Ltd Ordinary Share's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AFJK current and non-current assets.
Aimei Health Technology Co., Ltd Ordinary Share Competitors by Total Liabilities
The table below lists competitors of Aimei Health Technology Co., Ltd Ordinary Share ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
Turkey | TL2.35 Billion |
|
Daedong Gear Co. Ltd
KQ:008830
|
Korea | ₩190.40 Billion |
|
Mountain Crest Acquisition Corp V
NASDAQ:MCAG
|
USA | $3.85 Million |
|
Saeron Auto
KO:075180
|
Korea | ₩32.59 Billion |
|
Carnegie Clean Energy Limited
F:CNM1
|
Germany | €8.29 Million |
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
USA | $1.72 Million |
|
Tracxn Technologies Limited
NSE:TRACXN
|
India | Rs456.47 Million |
|
Ryde Group Ltd.
NYSE MKT:RYDE
|
USA | $5.01 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Aimei Health Technology Co., Ltd Ordinary Share's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Aimei Health Technology Co., Ltd Ordinar to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aimei Health Technology Co., Ltd Ordinary Share's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aimei Health Technology Co., Ltd Ordinary Share (2023–2025)
The table below shows the annual total liabilities of Aimei Health Technology Co., Ltd Ordinary Share from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.06 Million | +169.52% |
| 2024-12-31 | $1.51 Million | +110.82% |
| 2023-12-31 | $714.84K | -- |
About Aimei Health Technology Co., Ltd Ordinary Share
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other service sectors… Read more